PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB. Hematol Oncol 2021. [DOI: 10.1002/hon.42_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]

Early (¹⁸F) fluoro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin’s lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open